HCPLive Network

Plaque Psoriasis

The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx/Novartis) for adults with moderate to severe plaque psoriasis. The European Commission approved the same drug on Jan. 19. Its active ingredient is an antibody that binds to interleukin-17A and interferes with inflammation. The binding prevents that protein from triggering the inflammatory response that results in psoriasis patches.
Study shows ustekinumab more effective at certain doses and in treatment-naïve patients. Several factors associated with diminished treatment response also identified.
A trio of phase 3 trials will evaluate the safety and efficacy of certolizumab pegol evaluated for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
A round up of recent research results on plaque psoriasis treatment with itolizumab, apitherapy, and ponesimod.
Cosentyx (secukinumab) has been approved in Japan for the treatment of psoriasis vulgaris (also known as plaque psoriasis) and psoriatic arthritis.
Psoriasis is associated with a higher risk of developing chronic kidney disease and glomerulonephritis, according to a study published online Dec. 15 in the British Journal of Dermatology.
Plaque Psoriasis Upcoming Events
Paris, France
June 11-14, 2014
New York, NY
July 9-12, 2014
Chicago, IL
August 6-10, 2014
Louisville, KY
August 7-9, 2014
Las Vegas, NV
September 12-13, 2014
Sonoma, CA
September 24-27, 2014
Las Vegas, NV
October 16-19, 2014
Dallas, TX
October 24-26, 2014
Boston, MA
November 14-19, 2014
New Orleans, LA
April 27-29, 2015
Plaque Psoriasis Latest News
Plaque Psoriasis Clinical Trials